Inter-Pharma Express Inc.

　　　　　Our Team

　　Our consultants have worked on drug formulation research and development, prepared applications for new drugs to the FDA and similar bodies, worked in market development, GXP services and engineering service related to construction of pharmaceutical facilities in Japan and elsewhere.

　 We have established extensive network between Japan and other countries, which helps ensure that we are able to provide the most effective way to solve problems.

　Dr. David Jordan (Ph , B Pharm, MRPharmS)

Dr Jordan has 30 years of pharmaceuticals-related experience and has carried out market development work with GSK, Hoechst Marison, Rousesel, Boots, Qauintiles and others.
He has worked with the development teams of Sectral (Aventis), Zantac 300 (GSK), Ventadisk (GSK) and Lasoride (Aventis), and was involved in their development.
He established White Rose Consulting Ltd and now works as a consultant. The company provides services ranging from research and development to market surveys and market cultivation.

　Sansei Oka, BSc

Mr Oka has a wide range of experience such as formulation science technology, clinical supply managements, regulatory affairs, marketing and sales, in research based pharmaceutical company and excipient supplier.
Also have a wide range of human network among pharmaceutical industries, academia and authorities both in domestic and overseas.
Member of DDS, APST-J and AAPS
Major client: Fuji Film Co.,Ltd., LTT Bio-Pharma. Ltd. Sansho-Iyaku Co.,Ltd.
Representative for Quay-Pharmaceuticals Ltd., Bio-Image Research Ltd., and TCI Japan

　Mr. Akio Hayashi

Mr Hayashi has 30 years of engineering experience and has been involved in projects in Japan and overseas. He established the pharmaceutical engineering division in IHI (a large Japanese engineering contractor) and participated in IHI’s acquisition of Niigata Engineering Co., Ltd.
He has 15 years of experience in pharmaceutical engineering projects in Ireland and is familiar with contract services. Now, he is a partner of IPE and an executive member of the International Society for Pharmaceutical Engineering (ISPE).

　Mr. Keiji Ozawa

Mr. Ozawa has 30 years of experiences of pharmaceutical development and also preparation of the production facility. They have been included establishment of recipe, production method, specification & testing method, stability test and the bio-equivalency test for the formulation.
He also has experiences of scaling up study for pharmaceutical manufacturing and production method validations as chairman of the validation committee.
He has 8 years experience of plant manager of the pharmaceutical plant. During this term, he is the award winner of SOLVAY INNOVATION PIONNEER AWARD.

　Mr. Hiroto Miyamoto

Mr. Miyamoto graduated agricultural chemistry and joined major chemical industry. Engaged to food and pharmaceutical excipient business, mainly microcrystalline cellulose, as business unit manager of R&D, plant manager and general manger of quality assurance. Also was experienced sales & marketing as regional director of South East Asia.
He is also affiliated with Japan Pharmaceutical Excipients Council (JPEC), chaired the international harmonization committee until 2007. He chair GMP committee and guideline committee of JPEC now. Also belonged to the pharmaceutical excipients committee of PMDA: a branch committee of the Japanese pharmacopoeia investigation committee of NHWL, supporting to revise Japanese pharmacopoeia due to the international harmonization of excipients.

　Other consultants

A　：　One consultant has worked on diagnostic drug formulation development, and marketing in a Western pharmaceutical company. And furthermore, experienced the medical device development and marketing. Then he joined the member to establish the bio-venture and in charge of R&D, sales and marketing. He is also the consortium member for developing the SOP for the micro-dose testing guide line.

B　：　One has worked on drug formation development and research for many years, and has experience of working in a drug formation research institute. He is an expert in the clinical field and in CMC/GXP services.
He has further achievements with international associations.

C　：　One transferred from academia to a pharmaceutical company and worked on drug formation research and development. He is also an expert in training services.

D　：　One has worked on drug formation research and development for many years. He is an expert in CMC services. He has taken out numerous patents during his career.